A very sad thing happened today on Wallstreet. The S&P 500, a tortured and struggling, but once very talented index, has passed away, together with his wife, Nasdaq, reportedly due to the anger he caused others through his massive, unyielding, and incurable affliction with a mind crippling disease known as TRUMP DERANGEMENT SYNDROME, sometimes referred to as TDS. He was known to have driven people CRAZY by his raging obsession of President Donald J. Trump, with his obvious paranoia reaching new heights as the Trump Administration surpassed all goals and expectations of greatness, and with the Golden Age of America upon us, perhaps like never before.
May S&P and Nasdaq rest in peace!
"Andrangi argues that even in the best-case scenario, where demand for computing power continues to expand, Coreweave will struggle to make enough money to recoup the upfront costs of building the data centres, let alone make a decent return on investors’ money. If demand falters, the hardware becomes obsolete more quickly than planned, or firms start building their own data centres, then Coreweave could be in serious trouble, especially as it has taken on huge debts to finance its investment. Other red flags include the fact that the key insiders have started selling their shares in the company."
Next week is packed in terms of key macro data.
On Tue, we get a full employment report for Nov, the Oct non-farm payrolls print and Oct advance retail sales.
We then get Nov CPI on Thu.
Throughout the week, we’ll also get data for S&P manufacturing and services PMIs (Tue), existing home sales (Fri) and Dec final UMich (Fri)
Low key, yes. Lots of strains have become resistant to current meds and so a new one that works on the resistant strains is actually kind of a big deal. There's two new ones coming to market but INVA's can treat a broader range of people.
The biggest downside is per patient, antibiotics aren't super profitable. But aggregated over a lot of patients it can still be a boon.
It wouldn't move the needle at all for most major pharmaceutical companies, but for small companies it can be a gigantic boost--which is why I'm motly focusing on small-to-mid caps right now.
This Week’s Calendar
**Monday, Dec. 15**
* Homebuilder confidence index (December)
* More Data to Watch: Empire State manufacturing survey (December)
* Federal Reserve Officials Speaking: Fed Governor Stephen Miran, New York Fed President John Williams
* Key Earnings: Navan (NAVN)
**Tuesday, Dec. 16**
* U.S. employment report (November)
* More Data to Watch: U.S. retail sales (October), Business inventories (September), S&P flash U.S. Purchasing Managers Index (PMI) (December)
* Key Earnings: Lennar (LEN)
**Wednesday, Dec. 17**
* Federal Reserve Officials Speaking: Fed Governor Christopher Waller, New York President John Williams, Atlanta Federal President Raphael Bostic
* Key Earnings: Micron Technology (MU), Jabil (JBL), General Mills (GIS)
**Thursday, Dec. 18**
* Consumer Price Index (November)
* More Data to Watch: Initial jobless claims (Week ending Dec. 13), Philadelphia Fed manufacturing survey (December)
* Key Earnings: Accenture (ACN), Nike (NKE), Cintas (CTAS), FedEx (FDX), Darden Restaurants (DRI), Birkenstock (BIRK), CarMax (KMX), KB Home (KBH), BlackBerry (BB)
**Friday, Dec. 19**
* Existing-home sales (November)
* More Data to Watch: Consumer sentiment - final (December)
* Key Earnings: Paychex (PAYX), Carnival (CCL), Conagra (CAG), Lamb Weston (LW), Winnebago (WGO)
[https://finance.yahoo.com/news/nvidia-earnings-delayed-jobs-data-231045323.html](https://finance.yahoo.com/news/nvidia-earnings-delayed-jobs-data-231045323.html)